NCT01329796

Pertubation With Lignocaine in Endometriosis

Pertubation With Lignocaine in Endometriosis Associated Symptoms Effect Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Isifer AB · Industry
• Sex: Female
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Endometriosis is a disease of unknown aetiology that can cause severe dysmenorrhea. An altered immune system with elevated levels of cytokines in the peritoneal fluid as well as increased density of nerve fibres, might explain the pathophysiology of dysmenorrhea in endometriosis patients. Lignocaine has anti-inflammatory properties and exerts effect on nerve endings and intra peritoneal macrophages. Pertubation with lignocaine might represent an alternative treatment for endometriosis related dysmenorrhea and avoids the side-effects related to hormonal treatments. A double blind randomized clinical trial, was carried out to evaluate pertubation with lignocaine as a therapy for dysmenorrhea.

Conditions

• Endometriosis
• Dysmenorrhea

Interventions

Type	Name	Description
DRUG	Lignocaine	Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
DRUG	Ringers Solution	Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

Timeline

• Start date: 2007-03-01
• Primary completion: 2009-06-01
• Completion: 2010-03-01
• First posted: 2011-04-06
• Last updated: 2011-04-06

Locations

3 sites across 1 country: Sweden